• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure

    5/14/26 4:29:55 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    8-K
    false 0001937653 0001937653 2026-05-14 2026-05-14
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2026

     

     

    Zymeworks Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41535   88-3099146

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    108 Patriot Drive, Suite A

    Middletown, Delaware

      19709
    (Address of principal executive offices)   (Zip Code)

    (302) 274-8744

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.00001 per share   ZYME   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01 Other Events.

    On May 14, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing that its Board of Directors (the “Board”) had authorized a share repurchase program (the “2026 Share Repurchase Program”) under which the Company may repurchase up to $125.0 million of the Company’s common stock, par value $0.00001 per share (the “Common Stock”). In connection with approval of the 2026 Share Repurchase Program, the Board terminated the previous authorization of up to $125.0 million of repurchases of Common Stock (the “2025 Repurchase Program”), under which an aggregate of 4,197,553 shares of Common Stock were repurchased with an average price of $24.36 per share, for total repurchases of $102.3 million (exclusive of commission expense and estimated excise tax).

    A copy of the press release announcing the 2026 Share Repurchase Program is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 7.01 Regulation FD Disclosure.

    Based on current operating plans, and assuming full execution of the $125.0 million 2026 Share Repurchase Plan, the Company currently expects its existing cash resources as of March 31, 2026, when combined with anticipated regulatory milestone payments of $440.0 million related to the potential approvals of Ziihera in GEA in the U.S., Europe, Japan, and China, to fund its planned operations beyond 2028. This anticipated cash runway does not take into account any contribution from additional future milestone payments or royalties related to Ziihera, other current licensed product candidates or contributions from future partnerships and collaborations.

    The information in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act or the Exchange Act, regardless of any general incorporation language contained in such, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.

     


    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are identified by such words as “believe,” “expect,” “anticipate” and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company’s plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the anticipated sufficiency of existing cash resources as of March 31, 2026, when combined with anticipated regulatory milestone payments of $440.0 million related to the potential approvals of Ziihera in GEA in the U.S., Europe, Japan, and China, to fund the Company’s planned operations beyond 2028, assuming the potential full execution of the 2026 Share Repurchase Program. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are made, and the Company is not under any obligation and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

    ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

    (d) Exhibits

     

    Exhibit No.    Description
    99.1    Press Release, dated May 14, 2026.
    104    Cover Page Interactive Data File (embedded as Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

           

    ZYMEWORKS INC.

        (Registrant)
    Date: May 14, 2026     By:  

    /s/ Kenneth Galbraith

       

    Name:

    Title:

     

    Kenneth Galbraith

    Chair, President and Chief Executive Officer

    Get the next $ZYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    10/24/2025$15.00Equal Weight
    Wells Fargo
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    10/10/2025$30.00Buy
    B. Riley Securities
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ZYME
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.

    SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)

    5/15/26 4:09:19 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Zymeworks Inc. (0001937653) (Filer)

    5/14/26 4:29:55 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Zymeworks Inc.

    10-Q - Zymeworks Inc. (0001937653) (Filer)

    5/7/26 4:15:16 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

    VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36 per co

    5/14/26 4:05:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum: Zymeworks' management will participate in one-on-one meetings and a fireside chat on May 20 at 9:00 am Eastern Time (ET) virtually.TD Cowen 7th Annual Oncology Innovation Summit: Zymeworks' management will participate in a fireside chat on May 27 at 4:30 pm ET virtually.2026 Jefferies Global Healthcare Confe

    5/13/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

    Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026China's NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancersPresented on emerging RAS inhibitor antibody-drug co

    5/7/26 4:05:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Zymeworks with a new price target

    Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00

    10/24/25 9:02:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, General Counsel Schneider Paul R

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/15/26 5:00:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    5/15/26 4:55:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Schayowitz Adam

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/10/26 4:10:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

    • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e

    4/9/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Kristin Stafford as Chief Financial Officer

    VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a

    4/1/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Financials

    Live finance-specific insights

    View All

    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

    VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr

    4/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

    VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET). About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a

    2/12/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zymeworks Inc.

    SC 13G - Zymeworks Inc. (0001937653) (Subject)

    11/13/24 4:30:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care